Can Emgality (Galcanezumab) Cause Constipation?

Understanding Emgality and Its Digestive Effects

Emgality (galcanezumab) belongs to a newer class of migraine prevention medications called CGRP receptor antagonists. This monthly injection works by blocking calcitonin gene-related peptide (CGRP) receptors, which play a key role in migraine development. While highly effective for preventing migraines, some patients wonder whether Emgality might affect their digestive system.

CGRP receptors exist throughout the body, including in the gastrointestinal tract, where they help regulate normal digestive processes. When galcanezumab blocks these receptors to prevent migraines, it may also influence gut motility and bowel function in some individuals. Understanding this connection helps explain why some patients experience digestive changes after starting treatment.

Doctronic, which has achieved 99.2% treatment plan alignment with board-certified physicians across 22M+ AI consultations, can help evaluate potential medication side effects and provide guidance on managing digestive symptoms while maintaining effective migraine prevention.

Clinical Trial Evidence for Constipation Risk

Clinical trials provide valuable data about Emgality's potential to cause constipation. In phase 3 studies involving thousands of patients, constipation occurred in approximately 2-3% of participants receiving galcanezumab compared to 1-2% in placebo groups. While this represents a small increase in risk, it indicates that some individuals may experience digestive changes.

The constipation reported in these trials was generally mild to moderate in severity. Most patients who experienced this side effect could continue treatment while managing symptoms through lifestyle modifications. However, a small percentage of participants discontinued treatment due to intolerable digestive symptoms, including severe constipation.

Interestingly, other gastrointestinal side effects like nausea and dizziness were also reported, though constipation remained one of the more common digestive complaints. The onset typically occurred within the first few weeks to months of treatment, suggesting the body may adjust to the medication over time in some cases.

Comparing CGRP Inhibitors and Digestive Side Effects

Not all CGRP inhibitors have identical side effect profiles. Understanding these differences can help healthcare providers select the most appropriate treatment for individual patients.

While constipation rates appear similar across different CGRP inhibitors, individual responses can vary significantly. Some patients who experience digestive issues with one medication may tolerate another CGRP inhibitor better, making it worthwhile to discuss alternatives if constipation becomes problematic.

Why Emgality Might Affect Bowel Function

CGRP plays several important roles in normal digestive function. These receptors help regulate intestinal motility, the coordinated muscle contractions that move food and waste through the digestive system. When galcanezumab blocks CGRP receptors, it may inadvertently slow these normal contractions in some individuals.

Additionally, CGRP influences blood flow to the intestines and affects the enteric nervous system, which controls many aspects of digestion. Disrupting these pathways could theoretically contribute to constipation, particularly in people who are already prone to digestive issues or have slower baseline gut motility.

Individual sensitivity varies considerably. Some patients notice no digestive changes whatsoever, while others may experience constipation within weeks of starting treatment. Factors like age, overall health, concurrent medications, and existing digestive conditions may influence susceptibility to this side effect. Similar patterns occur with other medications, such as those discussed in Mounjaro Constipation? and Ozempic Constipation? articles.

Practical Management Strategies

If you develop constipation while taking Emgality, several approaches can help manage this side effect without compromising migraine prevention. Increasing dietary fiber gradually through fruits, vegetables, and whole grains often provides relief. Adequate hydration remains crucial, as dehydration can worsen constipation and potentially lead to stomach pain.

Regular physical activity, even light walking, can stimulate intestinal motility and promote regular bowel movements. Over-the-counter options like fiber supplements, stool softeners, or gentle laxatives may provide additional relief when used appropriately under healthcare provider guidance.

Timing can be important when implementing these strategies. Some patients find that starting dietary and lifestyle modifications before beginning Emgality helps prevent constipation from developing. Others may need to adjust their approach based on symptom severity and response to initial interventions.

When to Seek Medical Guidance

While mild constipation can often be managed independently, certain situations warrant prompt medical attention. Severe constipation lasting more than a few days, accompanied by back pain or abdominal cramping, should be evaluated by a healthcare provider.

If constipation significantly impacts your quality of life or doesn't respond to standard management approaches, discuss treatment alternatives with your provider. They might recommend adjusting the Emgality dosage, switching to a different CGRP inhibitor, or exploring non-CGRP migraine prevention options.

Severe digestive symptoms could also indicate complications unrelated to the medication. Conditions affecting better absorption of nutrients or other underlying health issues might require separate evaluation and treatment. Doctronic's 24/7 HIPAA-compliant platform can help assess concerning symptoms and determine when in-person evaluation is necessary.

The Bottom Line

While Emgality (galcanezumab) can potentially cause constipation, this side effect occurs in only 2-3% of patients according to clinical trial data. Most cases are mild and manageable through dietary adjustments, increased hydration, and over-the-counter treatments. The timing of symptom onset often helps determine whether the medication is responsible for digestive changes. Healthcare providers can work with patients to balance effective migraine prevention with digestive comfort, adjusting treatment plans when necessary. This article is informational and is not a medical diagnosis. Confirm with a licensed clinician, especially for new, worsening, or high-risk symptoms.